Johns Hopkins HIV Guide
Sofosbuvir + velpatasvir
INDICATIONS
FDA
FDA
Treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 without cirrhosis or with compensated cirrhosis or with decompensated cirrhosis in combination with ribavirin
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 27, 2020
Citation
Smith, Janessa M. "Sofosbuvir + Velpatasvir." Johns Hopkins HIV Guide, 2020. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir.
Smith JM. Sofosbuvir + velpatasvir. Johns Hopkins HIV Guide. 2020. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir. Accessed September 28, 2023.
Smith, J. M. (2020). Sofosbuvir + velpatasvir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir
Smith JM. Sofosbuvir + Velpatasvir [Internet]. In: Johns Hopkins HIV Guide. ; 2020. [cited 2023 September 28]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Sofosbuvir + velpatasvir
ID - 545302
A1 - Smith,Janessa,PharmD, BCPS
Y1 - 2020/07/27/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545302/all/Sofosbuvir_+_velpatasvir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
